Company

Fabre-Kramer Pharmaceuticals, Inc. (“FKP” or the “Company”), was formed to identify, develop and commercialize psychotropic drugs with significant market potential. Louis Fabre, M.D., Ph.D., Chairman of the Board of FKP, has over 30 years of experience in the clinical development of new psychotropic drugs and has conducted pivotal studies of most drugs approved by the FDA in psychiatry, including Prozac, Zoloft, Paxil, Effexor, Celexa, Seroquel, Zyprexa, and Abilify. Dr. Fabre has also been involved in clinical studies of numerous anxiolytic drugs, including BuSpar, and studies of drugs used to treat other psychiatric illnesses, including bipolar disorder, social phobia and sleep disorders. Stephen Kramer, M.D., Chief Executive Officer and President of FKP, has over 30 years experience in inpatient and outpatient psychiatry. Both doctors have intimate knowledge of the treatment of Central Nervous System (“CNS”) disorders and have analyzed many other potential psychotropic compounds from the standpoint of receptor activity, efficacy, tolerability, side effect/benefit ratio, formulation, ease of administration, cost, and ease of manufacturing.

The Company’s lead drug is Gepirone, a compound developed to treat depression and other related illnesses. The Company re-acquired Gepirone from its previous development partner (Organon), conducted a successful Phase III program, and recently filed an amendment to the NDA in May 2007. Worldwide commercialization rights were licensed to GlaxoSmithKline (www.gsk.com) in early 2007. Gepirone extended release (ER) is a 5HT1A partial agonist. Antidepressant effects are believed to be due to an agonist effect on post synaptic serotonin receptors. In November 2007, the FDA issued a non-approved letter for major depressive disorders. FKP is currently assessing further development opportunities for Gepirone for other indications.

In addition to Gepirone, FKP has continued to pursue opportunities to acquire and develop additional psychotropic drugs that it believes have significant market potential. The Company is in an excellent position to identify and acquire additional promising psychotropic drugs that, for a variety of reasons, are available from major pharmaceutical companies and other industry and academic sources. The compounds discussed in our Products section represent FKP's present pipeline.

In contrast to most pharmaceutical or biotechnology companies, FKP has lower overhead costs and has completed the development of a major new drug (Gepirone) with an extremely efficient use of capital. Additional drugs are also being developed on FKP’s more efficient outsourced structure and accelerated timelines. FKP can economically and efficiently further develop these products, and then outlicense them for the completion of development and marketing. FKP has developed this pipeline of pharmaceutical products at costs far below those of major pharmaceutical companies; and expects to be an attractive acquisition candidate to companies seeking a major presence in the CNS therapy area. Additionally, as a multi-product company with an attractive pipeline of product opportunities, the Company will consider outlicensing individual compounds or groups of compounds, as well as raising additional capital from institutional investors to further develop the compounds.

FKP was formed in 1992, and has been funded to date largely by the capital of its founders. A small group of private individuals own approximately 5% of the Company. There are no institutional or venture capital shareholders. Milestone payments and products sales under licensing agreements have provided additional funding.